Standard BioTools Inc. (NASDAQ:LAB) Shares Bought by Royce & Associates LP

Royce & Associates LP raised its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 136.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,455,503 shares of the company’s stock after buying an additional 840,951 shares during the quarter. Royce & Associates LP’s holdings in Standard BioTools were worth $2,547,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. HighTower Advisors LLC raised its holdings in shares of Standard BioTools by 13.0% in the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after buying an additional 10,690 shares during the last quarter. Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of Standard BioTools during the fourth quarter valued at $314,000. SG Americas Securities LLC increased its position in shares of Standard BioTools by 34.2% in the 4th quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock valued at $238,000 after acquiring an additional 34,670 shares during the period. Simon Quick Advisors LLC purchased a new position in Standard BioTools in the 4th quarter worth $54,000. Finally, JPMorgan Chase & Co. lifted its position in Standard BioTools by 7.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after acquiring an additional 9,995 shares during the period. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Price Performance

LAB stock opened at $1.16 on Friday. The company has a market capitalization of $439.62 million, a P/E ratio of -1.63 and a beta of 1.62. Standard BioTools Inc. has a 12 month low of $0.99 and a 12 month high of $3.04. The firm’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $1.72.

Insider Activity at Standard BioTools

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were purchased at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the acquisition, the director now directly owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 53.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, KeyCorp lowered Standard BioTools from an “overweight” rating to a “sector weight” rating in a report on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.